Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment

Abstract Surgical cytoreduction combined with intraperitoneal chemo-hyperthermia (HIPEC) has shown to provide survival benefits in the management of some peritoneal carcinomatosis. The cisplatin (CP) used in HIPEC carries a risk of renal impairment (RI). This risk could be reduced by administration...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2016-02, Vol.42 (2), p.219-223
Main Authors: Bouhadjari, N, Gabato, W, Calabrese, D, Msika, S, Keita, H
Format: Article
Language:English
Subjects:
Acute Kidney Injury - etiology
Acute Kidney Injury - physiopathology
Acute Kidney Injury - prevention & control
Adenocarcinoma - secondary
Adenocarcinoma - therapy
Adult
Aged
Amifostine
Amifostine - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Colorectal Neoplasms - secondary
Creatinine - blood
Creatinine - urine
Cytoreduction Surgical Procedures
Female
Free Radical Scavengers - therapeutic use
Hematology, Oncology and Palliative Medicine
Humans
Hyperthermia, Induced - adverse effects
Hyperthermic intraperitoneal chemotherapy
Infusions, Parenteral
Male
Middle Aged
Mitomycin - administration & dosage
Ovarian Neoplasms - secondary
Peritoneal Neoplasms - secondary
Peritoneal Neoplasms - therapy
Pseudomyxoma Peritonei - therapy
Renal impairment
Retrospective Studies
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Surgical cytoreduction combined with intraperitoneal chemo-hyperthermia (HIPEC) has shown to provide survival benefits in the management of some peritoneal carcinomatosis. The cisplatin (CP) used in HIPEC carries a risk of renal impairment (RI). This risk could be reduced by administration of amifostine (A). The aim of our study was to assess the utility of A in preventing RI during IPCH with CP. Patients and methods Retrospective study including patients who underwent HIPEC between January 2007 and June 2013. The HIPEC involved administration of CP and mitomycin C, between 41 and 43 °C. The peri-anaesthetic management was consistent to use A after 2010. Renal function was assessed from the measured creatinine clearance (CreatCl) and the change between D0 and D4 was compared between patients who received A (group A+) and those who did not (group A−). Severe RI was defined as the development of a CreatCl of
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2015.07.016